P. Murali Doraiswamy
Professor of Psychiatry and Behavioral Sciences
Murali Doraiswamy is a doctor and translational scientist at Duke University where he directs a clinical trials unit developing novel technologies and treatments for enhancing brain health. He has served as an advisor to leading businesses, government agencies and patient advocacy groups.
Murali has been a health advisor for Men's Health magazine and AARP Magazine, and is a co-author of a popular book, The Alzheimer's Action Plan. His research has been featured in media outlets such as The New York Times, Oprah, Dr Oz Show, CBS Morning, Discovery, BBC, USA Today, NPR, and BBC.
Dr. Doraiswamy is a member of the World Economic Forum's Global Future Councils.
Racial and Geographic Disparities in Risk and Survival of Alzheimer's Disease and Related Dementias awarded by National Institutes of Health (Senior Investigator). 2019 to 2024
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Gut Liver Brain Biochemical Axis in Alzheimer's Disease awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Predicting prebiotic effects on human microbiota, behavior, and cognition. awarded by Office of Naval Research (Collaborator). 2018 to 2021
Does rifaximin improve cognition in patients with Alzheimer's disease?" using Manufacturer's drug XIFAXAN awarded by (Co Investigator). 2019 to 2021
Phase 3 Clinical Trial for Agitation in Alzheimer's 15-AVP-786-301 awarded by (Principal Investigator). 2016 to 2020
Phase 3 Clinical Trial for Agitation in Alzheimer's 15-AVP-786-303 awarded by (Principal Investigator). 2016 to 2020
Effects of Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder (PTSD) on Alzheimer's Disease (AD) in Veterans Using Imaging and Biomarkers in the AD Neuroimaging Initiative (ADNI) (DoD) awarded by University of Southern California (Principal Investigator). 2015 to 2020
Effects of Traumatic Brain Injury and Post-Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans with Mild Cognitive Impairment (MC) using the Alzheimer's disease neuroimaging initiative awarded by University of Southern California (Principal Investigator). 2015 to 2020
Horgusluoglu-Moloch, Emrin, et al. “Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways..” Sci Rep, vol. 9, no. 1, Oct. 2019. Pubmed, doi:10.1038/s41598-019-50507-3. Full Text
Goudey, Benjamin, et al. “A blood-based signature of cerebrospinal fluid Aβ1-42 status..” Sci Rep, vol. 9, no. 1, Mar. 2019. Pubmed, doi:10.1038/s41598-018-37149-7. Full Text
Nho, Kwangsik, et al. “Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers..” Alzheimers Dement, vol. 15, no. 2, Feb. 2019, pp. 232–44. Pubmed, doi:10.1016/j.jalz.2018.08.012. Full Text
MahmoudianDehkordi, Siamak, et al. “Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome..” Alzheimers Dement, vol. 15, no. 1, Jan. 2019, pp. 76–92. Pubmed, doi:10.1016/j.jalz.2018.07.217. Full Text Open Access Copy
Petrella, Jeffrey R., et al. “Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease..” Comput Math Methods Med, vol. 2019, 2019. Pubmed, doi:10.1155/2019/6216530. Full Text
Sohn, Dongwha, et al. “Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease..” Sci Rep, vol. 8, no. 1, May 2018. Pubmed, doi:10.1038/s41598-018-25377-w. Full Text
Lu, Donghuan, et al. “Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images..” Sci Rep, vol. 8, no. 1, Apr. 2018. Pubmed, doi:10.1038/s41598-018-22871-z. Full Text
Mills, Paul J., et al. “Change in Sense of Nondual Awareness and Spiritual Awakening in Response to a Multidimensional Well-Being Program..” J Altern Complement Med, vol. 24, no. 4, Apr. 2018, pp. 343–51. Pubmed, doi:10.1089/acm.2017.0160. Full Text
Mahjoub, Ines, et al. “Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states..” Sci Rep, vol. 8, no. 1, Mar. 2018. Pubmed, doi:10.1038/s41598-018-21568-7. Full Text
Privitera, Gregory J., et al. “No calorie comfort: Viewing and drawing "comfort foods" similarly augment positive mood for those with depression..” J Health Psychol, vol. 23, no. 4, Mar. 2018, pp. 598–607. Pubmed, doi:10.1177/1359105316681861. Full Text
Harenberg, S., et al. “Knowledge-guided maximal clique enumeration.” Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 10086 LNAI, 2016, pp. 604–18. Scopus, doi:10.1007/978-3-319-49586-6_43. Full Text
Doraiswamy, P. Murali, et al. “Preimplantation Genetic Diagnosis (PGD) for Familial Alzheimer's Disease Due To PSEN1 Mutation.” Annals of Neurology, vol. 76, WILEY-BLACKWELL, 2014, pp. S90–S90.
Hochstetler, Helen, et al. “Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S136–S136. Crossref, doi:10.1016/j.jagp.2012.12.180. Full Text
Witte, Michael, et al. “Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S138–39. Crossref, doi:10.1016/j.jagp.2012.12.183. Full Text
Sheldon, F. C., et al. “Disruption of Functional Brain Connections in Alzheimer's Disease.” Journal of Nuclear Medicine, vol. 51, no. 5, SOC NUCLEAR MEDICINE INC, 2010, pp. 828–29.
Doraiswamy, P. Murali, et al. “In Cognitively Healthy and Mildly Impaired Individuals Florbetapir F 18 PET Measures of Amyloid Deposition Correlate with the Degree of Functional Impairment Assessed Six Months Later.” Neurology, vol. 74, no. 9, LIPPINCOTT WILLIAMS & WILKINS, 2010, pp. A338–A338.
Doraiswamy, P. Murali, et al. “Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients.” Biological Psychiatry, vol. 63, no. 7, ELSEVIER SCIENCE INC, 2008, pp. 283S-284S.
Kaddurah-Daouk, Rima, et al. “Metabolomic mapping of schizophrenia and atypical antipsychotic effects.” Biological Psychiatry, vol. 61, no. 8, ELSEVIER SCIENCE INC, 2007, pp. 164S-164S.
Szarfman, A., et al. “Risperidone and pituitary tumors: a pharmacovigilance study.” Bipolar Disorders, vol. 7, BLACKWELL PUBLISHING, 2005, pp. 116–17.
Pomara, N., et al. “Elevated plasma A beta(1-42) in geriatric depression.” Biological Psychiatry, vol. 57, no. 8, ELSEVIER SCIENCE INC, 2005, pp. 200S-200S.